Form 4: Arbutus Biopharma Director Acquires Stock Options

Robert A. Beardsley, a director of Arbutus Biopharma Corp, was granted stock options to purchase 157,600 common shares.

Summary

• On March 18, 2025, Robert A. Beardsley, a director of Arbutus Biopharma Corp, was granted stock options.
• The options allow him to purchase 157,600 common shares at an exercise price of $3.20 per share.
• The options vest over a three-year period, with one-third of the shares vesting annually on the anniversary of the grant date, contingent upon continuous service.
• Following the transaction, Beardsley directly owns 157,600 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to stock option grants, which is generally neutral. It reflects standard compensation practices.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, aligning the interests of directors with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Gilead Sciences, Amgen, and Vertex Pharmaceuticals also utilize stock options as part of their compensation strategy to attract and retain key personnel.
• The vesting schedule of three years is also typical within the industry.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
• The grant has a dilutive effect on existing shareholders, although the impact is likely minimal given the size of the grant relative to the company's total outstanding shares.

Key Dates

Keywords

stock options, Form 4, director, ABUS, Arbutus Biopharma, beneficial ownership